Related references
Note: Only part of the references are listed.SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases
Joanne Elliott et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
PU.1 and partners: regulation of haematopoietic stem cell fate in normal and malignant haematopoiesis
Pallavi Gupta et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation
Franck Morceau et al.
BIOFACTORS (2008)
PU.1 expression is restored upon treatment of chronic myeloid leukemia patients
Marta Albajar et al.
CANCER LETTERS (2008)
SOCS regulation of the JAK/STAT signalling pathway
Ben A. Croker et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Canonical and non-canonical JAK-STAT signaling
Willis X. Li
TRENDS IN CELL BIOLOGY (2008)
Recurrent gene fusions in prostate cancer
Chandan Kumar-Sinha et al.
NATURE REVIEWS CANCER (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
The expression of SOCS is altered in rheumatoid arthritis
P. Isomaeki et al.
RHEUMATOLOGY (2007)
JAK-STAT signaling: From interferons to cytokines
Christian Schindler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Michelle B. Hookham et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
GM-CSF regulates a PU.1-dependent transcriptional program determining the pulmonary response to LPS
Pierre-Yves Berclaz et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
BCR-ABL activates STAT3 via JAK and MEK pathways in human cells
Paul Coppo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
H Quentmeier et al.
LEUKEMIA (2006)
EWS-ETS oncoproteins: The linchpins of Ewing tumors
R Janknecht
GENE (2005)
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
AV Jones et al.
BLOOD (2005)
Mechanisms of disease: Acute lymphoblastic leukemia
C Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
PU.1 supports proliferation of immature erythroid progenitors
RC Fisher et al.
LEUKEMIA RESEARCH (2004)
CDK6 blocks differentiation: coupling cell proliferation to the block to differentiation in leukemic cells
I Matushansky et al.
ONCOGENE (2003)
Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression
T Schroeder et al.
JOURNAL OF IMMUNOLOGY (2003)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
The ETS-domain transcription factor family
AD Sharrocks
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fcγ receptor I in monocytes
S Aittomäki et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
